The Impact of Prophylactic Post-Chemotherapy G-CSF on the Relapse Rates in Patients with Acute Myeloid Leukemia: A Meta-Analysis

References

• Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996;88(6):1907–1929. doi:10.1182/blood.V88.6.1907.bloodjournal8861907.
   PubMed Web of Science ®Google Scholar
• Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood. 1996;88(10):3675–3685. doi:10.1182/blood.V88.10.3675.bloodjournal88103675.
   PubMed Web of Science ®Google Scholar
• Smith M, Singer C, Pallister C, Smith J. The effect of haemopoietic growth factors on the cell cycle of AML progenitors and their sensitivity to cytosine arabinoside in vitro. Br J Haematol. 1995;90(4):767–773. doi:10.1111/j.1365-2141.1995.tb05194.x.
   PubMed Web of Science ®Google Scholar
• Beekman R, Touw IP. G-CSF and its receptor in myeloid malignancy. Blood. 2010;115(25):5131–5136. doi:10.1182/blood-2010-01-234120.
   PubMed Web of Science ®Google Scholar
• Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol. 2010;28(3):275–280. doi:10.1038/nbt.1607.
   PubMed Web of Science ®Google Scholar
• Vellenga E, Young DC, Wagner K, Wiper D, Ostapovicz D, Griffin JD. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood. 1987;69(6):1771–1776. doi:10.1182/blood.V69.6.1771.1771.
   PubMed Web of Science ®Google Scholar
• Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol. 1996;14(7):2150–2159. doi:10.1200/jco.1996.14.7.2150.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Touw IP. Hematopoietic growth factors and their receptors in acute leukemia. Blood. 1993;81(2):281–292. doi:10.1182/blood.V81.2.281.bloodjournal812281.
   PubMed Web of Science ®Google Scholar
• Feng X, Lan H, Ruan Y, Li C. Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis. Hematology. 2018;23(9):581–589. doi:10.1080/10245332.2018.1446811.
   PubMed Web of Science ®Google Scholar
• Sung L, Alibhai S, Beyene J, Gamis A, Almeida R, Smith S, Aplenc R. Hematopoietic colony-stimulating factor priming does not influence survival in acute myeloid leukemia: a meta-analysis of randomized trials. Leukemia. 2009;23(4):811–813. doi:10.1038/leu.2008.305.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–3167. doi:10.1200/jco.2006.08.8823.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205. doi:10.1200/jco.2006.06.4451.
   PubMed Web of Science ®Google Scholar
• Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198–4214. doi:10.1200/jco.2005.05.645.
   PubMed Web of Science ®Google Scholar
• Wittman B, Horan J, Lyman GH. Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat Rev. 2006;32(4):289–303. doi:10.1016/j.ctrv.2006.03.002.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W64. doi:10.7326/0003-4819-151-4-200908180-00135.
   PubMed Web of Science ®Google Scholar
• Tarsilla M. Cochrane handbook for systematic reviews of interventions. J Multidiscip Eval. 2010;6(14):142–148. doi:10.56645/jmde.v6i14.284.
   Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi:10.1136/bmj.315.7109.629.
   PubMed Web of Science ®Google Scholar
• Beksac M, Ali R, Ozcelik T, Ozcan M, Ozcebe O, Bayik M, et al. Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial. Leuk Res. 2011;35(3):340–345. doi:10.1016/j.leukres.2010.07.005.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24(27):4499–4506. doi:10.1200/jco.2006.06.5037.
   PubMed Web of Science ®Google Scholar
• Czerw T, Labopin M, Gorin N-C, Giebel S, Blaise D, Dumas P-Y, et al. Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2014;49(7):950–954. doi:10.1038/bmt.2014.64.
   PubMed Web of Science ®Google Scholar
• Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med. 1995;332(25):1678–1683. doi:10.1056/nejm199506223322504.
   PubMed Web of Science ®Google Scholar
• Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031). Blood. 1998;91(10):3607–3615. doi:10.1182/blood.V91.10.3607.
   PubMed Web of Science ®Google Scholar
• Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie J-P, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005;106(1):27–34. doi:10.1182/blood-2004-09-3728.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Witz B, Lioure B, Hunault-Berger M, Desablens B, Delain M, et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. J Clin Oncol. 2000;18(4):780–787. doi:10.1200/jco.2000.18.4.780.
   PubMed Web of Science ®Google Scholar
• Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 1997;90(12):4710–4718. doi:10.1182/blood.V90.12.4710.4710_4710_4718.
   PubMed Web of Science ®Google Scholar
• Kang KW, Kim DS, Lee SR, Sung HJ, Kim SJ, Choi CW, et al. Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7 + 3 regimen) chemotherapies. Leuk Res. 2017;57:1–8. doi:10.1016/j.leukres.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Creutzig U. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood. 2007;109(3):936–943. doi:10.1182/blood-2006-07-035915.
   PubMed Web of Science ®Google Scholar
• Løhmann DJA, Asdahl PH, Abrahamsson J, Ha S-Y, Jónsson ÓG, Kaspers GJL, et al. Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01. Pediatr Blood Cancer. 2019;66(6):e27701. doi:10.1002/pbc.27701.
   PubMed Web of Science ®Google Scholar
• Moore JO, Dodge RK, Amrein PC, Kolitz J, Lee EJ, Powell B, et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood. 1997;89(3):780–788. doi:10.1182/blood.V89.3.780.
   PubMed Web of Science ®Google Scholar
• Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H, Hamajima N, et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol. 2002;116(1):103–112. doi:10.1046/j.1365-2141.2002.03251.x.
   PubMed Web of Science ®Google Scholar
• Wheatley K, Goldstone AH, Littlewood T, Hunter A, Burnett AK. Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol. 2009;146(1):54–63. doi:10.1111/j.1365-2141.2009.07710.x.
   PubMed Web of Science ®Google Scholar
• Oberson JS, Novak U, Mansouri Taleghani B, Baerlocher GM, Seipel K, Mueller B, et al. Revisiting G-CSF support for hematologic recovery after autologous transplantation in AML patients. Ann Hematol Oncol. 2017;4(5):1148.
   Google Scholar
• Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol. 2004;22(16):3350–3356. doi:10.1200/jco.2004.09.106.
   PubMed Web of Science ®Google Scholar
• Ravandi F. Role of cytokines in the treatment of acute leukemias: a review. Leukemia. 2006;20(4):563–571. doi:10.1038/sj.leu.2404152.
   PubMed Web of Science ®Google Scholar
• Ehlers S, Herbst C, Zimmermann M, Scharn N, Germeshausen M, von Neuhoff N, et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol. 2010;28(15):2591–2597. doi:10.1200/jco.2009.25.9010.
   PubMed Web of Science ®Google Scholar
• Kutlay S, Beksac M, Dalva K, Ilhan O, Koc H, Akan H, Ozcan M. The detection of flow cytometric G-CSF receptor expression and it’s effect on therapy in acute myeloid leukemia. Leuk Lymphoma. 2003;44(5):791–795. doi:10.1080/1042819031000067512.
   PubMed Web of Science ®Google Scholar
• Wang J, An L, Chen S, Ouyang J, Zhou R, Chen B, Yang Y. Prophylactic use of granulocyte colony-stimulating factor after chemotherapy does not affect survival rate in acute myeloid leukemia: a meta-analysis. Acta Haematol. 2009;121(4):223–226. doi:10.1159/000225909.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhan P, Ouyang J, Chen B, Zhou R. Prophylactic use of granulocyte colony-stimulating factor after induction chemotherapy in patients with newly diagnosed acute myeloid leukemia may increase the complete remission rate: a meta-analysis of five randomised controlled trials. Leuk Lymphoma. 2009;50(3):457–459. doi:10.1080/10428190802654501.
   PubMed Web of Science ®Google Scholar
• Geller RB. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol. 1996;14(4):1371–1382. doi:10.1200/jco.1996.14.4.1371.
   PubMed Web of Science ®Google Scholar
• Gurion R, Belnik-Plitman Y, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev. 2012;2012(6):CD008238. doi:10.1002/14651858.CD008238.pub3.
   PubMedGoogle Scholar
• Heuser M, Zapf A, Morgan M, Krauter J, Ganser A. Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. Ann Hematol. 2011;90(3):273–281. doi:10.1007/s00277-010-1069-z.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24(10):2475–2484. doi:10.1093/annonc/mdt226.
   PubMed Web of Science ®Google Scholar
• Ding SX, Chen T, Wang T, Liu CY, Lu WL, Fu R. The risk of clonal evolution of granulocyte colony-stimulating factor for acquired aplastic anemia: a systematic review and meta-analysis. Acta Haematol. 2018;140(3):141–145. doi:10.1159/000491816.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Wolff DA, Culakova E, Poniewierski MS, Kuderer NM, Crawford J. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28(17):2914–2924. doi:10.1200/jco.2009.25.8723.
   PubMed Web of Science ®Google Scholar